--- title: "Eloxx reports second-quarter results after a $66.0 million offering" url: "https://aibio.space/news/eloxx-reports-second-quarter-results-after-66-0-million-offering/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-11" section: "Listings" tickers: "NASDAQ:ELOX" source: "https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/d167833dex991.htm" summary: "The company said its June offering and move to the Nasdaq Capital Market strengthened its balance sheet. Cash of $62.0 million is expected to fund operatio" --- By the aibio.space news desk. Sources - [Eloxx Pharmaceuticals Form 8-K, Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/d167833dex991.htm) - [Eloxx Pharmaceuticals, Inc. 10-K (2026-03-17): business](https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/elox-20251231.htm) - [Eloxx Pharmaceuticals, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/) [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/) 2026-08-11 # Eloxx reports second-quarter results after a $66.0 million offering and Nasdaq uplisting Tickers [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/) The company said its June offering and move to the Nasdaq Capital Market strengthened its balance sheet. Cash of $62.0 million is expected to fund operations into mid-2028. ## Key facts - **Company**: Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) - **News type**: Listings - **Primary source**: [Eloxx Pharmaceuticals Form 8-K, Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/d167833dex991.htm) *The White House and its lawn. CC0, via rawpixel. The picture shows the field, not the companies named.* Eloxx Pharmaceuticals, Inc. (Nasdaq: [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/)) reported financial results for the quarter ended June 30, 2026, in a release issued on August 11, 2026. The results cover a quarter in which the company completed an underwritten public offering and moved its stock to the Nasdaq Capital Market. The company is a clinical-stage biopharmaceutical company developing exaluren for rare kidney diseases. ## The offering and uplisting The company sold 2,975,000 shares of common stock at a public offering price of $11.00 per share, together with pre-funded warrants to purchase up to 3,025,000 shares. Gross proceeds were approximately $66.0 million and net proceeds were approximately $58.3 million, after underwriting discounts and commissions and offering expenses. The pre-funded warrants add to the potential share count beyond the 2,975,000 common shares sold. The sources used for this story do not name the underwriter or placement agent for the offering. In June 2026 the company completed its uplisting to the Nasdaq Capital Market, where its common stock began trading under the symbol ELOX. The release says a one-for-eleven reverse stock split took effect in May 2026, and that the company cut its authorized common stock from 500,000,000 to 100,000,000 shares. All share and per-share amounts in the release reflect the split. ## Second-quarter results The net loss for the three months ended June 30, 2026, was $4.5 million, or $(0.39) per share, including $0.1 million of stock-based compensation. The same quarter of 2025 showed a net loss of $1.9 million, or $(5.45) per share. For the six months ended June 30, 2026, the net loss was $8.3 million, compared with $3.6 million a year earlier. Research and development expenses were $2.8 million for the quarter, up from $0.9 million, which the company attributed mainly to clinical trial expenses for exaluren, along with higher personnel costs and preclinical work. General and administrative expenses were $1.6 million, up from $0.7 million, mainly because of higher professional and consulting fees and personnel costs. As of June 30, 2026, the company had cash and cash equivalents of $62.0 million. That figure includes approximately $58.3 million in net proceeds from the June offering. The company believes that cash will be sufficient to fund its operations into mid-2028, which is its own estimate. Year-end 2025 cash and cash equivalents were $4.8 million in the XBRL data, so the balance sheet rests on this one raise, and the quarter's loss was more than double the year-earlier loss. Chief executive Sumit Aggarwal said, "The second quarter was transformational for Eloxx." ## Pipeline and what comes next The company received clearance from the FDA under its Investigational New Drug application to proceed with a Phase 2b trial of exaluren in nonsense mutation Alport syndrome. It plans to start the trial in the third quarter of 2026. The release reports no efficacy results for exaluren in Alport syndrome. Topline data from the initial 16-week placebo-controlled portion are expected by mid-2027, with the final readout by the end of 2027. Exaluren has orphan drug designation from the FDA and the European Commission for Alport syndrome. In ADPKD, the European Commission granted orphan medicinal product designation for exaluren in July 2026. The company plans to start a Phase 2 trial in nonsense mutation ADPKD in 2027, with topline data anticipated by mid-2028. As in Alport, no human efficacy data for this use appear in the release, and the 10-K warns that competitors with drugs further along may reach the market first. The company also reported that its board added Stephen W. Webster and Nina Kjellson in May 2026. Eloxx has licensed its candidate ZKN-013 to Almirall, S.A., which is developing it for rare dermatological diseases. The company remains eligible for development and sales milestones of up to approximately $470.0 million, plus tiered royalties on future global sales. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ELOX Eloxx Pharmaceuticals, Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/eloxx-reports-second-quarter-results-after-66-0-million-offering/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Eloxx reports second-quarter results after a $66.0 million offering", 2026-08-11, https://aibio.space/news/eloxx-reports-second-quarter-results-after-66-0-million-offering/